Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

SCREEN-WELL® FDA approved drug library V2

Accelerates drug optimization with a unique collection of compounds of known safety and bioavailability for diverse targets.
 
BML-2843-0100 1 Library 100 µl/well Inquire for pricing
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-2841

  • Compounds can be used for diverse drug discovery in the fields of cardiology, neuropsychiatry, immunology, oncology and more!
  • Contains more than 100 additional compounds compared to our previous FDA approved library versions
  • 100% known bioactivity and greatest degree of drug-likeness available
  • Recently approved FDA compounds are also included
  • We provide detailed information in our comprehensive documentation for each compound
Drug repositioning or repurposing can be an important part of any drug discovery program and has led to several blockbuster drugs (e.g. Viagra and Rogaine). High-content screens, new biomarkers and noninvasive imaging techniques have created new opportunities for pursuing novel indications for approved compounds. Being FDA approved and in use in the clinics, all of the compounds in SCREEN-WELL® FDA v. 2.0 Approved Drug Library have known and well-characterized bioactivity, safety and bioavailability - properties which could dramatically accelerate drug development and optimization. The library also avoids irrelevant compounds found in similar libraries, such as herbicides, insecticides, sunscreen agents, and cytotoxic agents. This set provides one of the richest sources of bioactives and offers the greatest degree of drug-likeness available. Hits from this set will provide a significant head start in any drug optimization program. Many of the compounds included can also be provided as standalone compounds for further testing.

Product Specification

Applications:HTS
 
Kit/Set Contains:Over 770 compounds, selected to maximize chemical and pharmacological diversity
 
Quantity:100µl per well
 
Concentration:10 mM* in DMSO**

*Compounds are predominantly at concentration of 10mM unless otherwise stated.
**Compounds are predominantly provided in DMSO. Selected compounds are dissolved in nuclease-free water.
 
Use/Stability:Stable for at least one year from the date of receipt when stored at -80°C.
 
Shipping:Shipped on Dry Ice
 
Long Term Storage:-80°C
 
Technical Info/Product Notes:
 

Product Literature References

Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses: F.S. Varghese, et al.; Antiviral Res. 126, 117 (2016), Application(s): Screening and primary validation, Abstract;
Electrophysiology-Based Assays to Detect Subtype-Selective Modulation of Human Nicotinic Acetylcholine Receptors: G.E. Kirsch, et al.; Assay Drug Dev. Technol. 14, 333 (2016), Application(s): Assay ability test of profiling nicotinic receptors for subtype-selective modulatory effects, Abstract; Full Text
Identification of FDA-approved drugs that target hepatitis B virus transcription: M.A. van de Klundert, et al.; J. Viral. Hepat. 23, 191 (2016), Abstract;
Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening: V.R. Pothineni, et al.; Drug Des. Devel. Ther. 10, 1307 (2016), Application(s): Lyme disease treatment, Abstract; Full Text
New role for FDA-approved drugs in combating antibiotic-resistant bacteria: J.A. Andersson, et al.; Antimicrob. Agents Chemother. 60, 3717 (2016), Abstract;
Potential of l-thyroxine to differentiate osteoblast-like cells via Angiopoietin1: S.H. Park, et al.; Biochem. Biophys. Res. Commun. 478, 1409 (2016), Application(s): Library screened with adapted ELISA system to identify novel drugs that possibly promote differentiation of osteoblast-like cells by inducing Ang1 expression, Abstract;
Small molecule activation of apurinic/apyrimidinic endonuclease 1 reduces DNA damage induced by cisplatin in cultured sensory neurons: M.M. Georgiadis, et al.; DNA Repair (Amst.) 41, 32 (2016), Application(s): Cell culture, Abstract;
Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model: A. Shim, et al.; Sci. Rep. 6, 23110 (2016), Application(s): Antiviral activity of ICZ against HRVs detected by in vitro screening, Abstract; Full Text
Development and use of assay conditions suited to screening for and profiling of SET-domain-targeted inhibitors of the MLL/SET1 family of lysine methyltransferases: J.J. Ferry, et al.; Assay Drug Dev. Technol. 13, 221 (2015), Abstract; Full Text
Identification of trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual secretion-based promoter assay: S. Schulze, et al.; Pharma. Res. Per. 3, e00109 (2015), Application(s): Cell Culture, Full Text
Mevalonate pathway regulates cell size homeostasis and proteostasis through autophagy: T.P. Miettinen, et al.; Cell Rep. 13, 2610 (2015), Application(s): Identification of mechanisms related to cell size control, Abstract;
3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions: C. Wenzel, et al.; Exp. Cell Res. 323, 131 (2014), Abstract;
A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion: C. Voisset, et al.; Dis. Model Mech. 7, 435 (2014), Abstract; Full Text
Antifungal Application of Nonantifungal Drugs: M. Stylianou, et al.; Antimicrob. Agents Chemother. 58, 1055 (2014), Application(s): In vitro susceptibility testing of C. albicans strain SC5314, Abstract; Full Text
Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy : T.A. Waugh, et al.; Hum. Mol. Genet. 23, 4651 (2014), Application(s): Drug screening in zebrafish model of Duchenne muscular dystrophy, Abstract;
Host-Directed Antimicrobial Drugs with Broad-Spectrum Efficacy against Intracellular Bacterial Pathogens: D.M. Czyz, et al.; MBio. 5, e01534 (2014), Application(s): Screening of FDA-approved drugs for compounds that block the intracellular growth of C. burnetii in THP-1 cells, Abstract; Full Text
Fluorescent dye cocktail for multiplex drug-site mapping on human serum albumin: J.C. Er, et al.; ACS Comb. Sci. 15, 452 (2013), Abstract;
Miniature short hairpin RNA screens to characterize antiproliferative drugs: S. Kittanakom, et al.; G3 (Bethesda) 3, 1375 (2013), Application(s): Screening of A549 cells, Abstract; Full Text
Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay: R. Mao, et al.; Biochem. Pharmacol. 85, 1513 (2013), Abstract;
The toll-like receptor agonist imiquimod is active against prions: N. Oumata, et al.; PLoS One 8, e72112 (2013), Abstract; Full Text
Identification of Modulators of Hair Cell Regeneration in the Zebrafish Lateral Line: P. Namdara, et al.; J. Neurosci. 32, 3516 (2012), Application(s): Chemical screen for modulators of hair cell regeneration using zebrafish lateral line neuromasts as a platform, Abstract; Full Text
Systematic identification of synergistic drug pairs targeting HIV: X. Tan, et al.; Nat. Biotechnol. 30, 1125 (2012), Abstract;

General Literature References

Fish in a dish: drug discovery for hearing habilitation: R. Esterberg, et al.; Drug Discov. Today Dis. Models 10, 10.1016 (2013), Abstract; Full Text
A Bioluminogenic HDAC Activity Assay: Validation and Screening: F. Halley et al.; J. Biomol. Screen. 16, 1227 (2011), Abstract;
Cell line and drug-dependent effect of ERBB3 on cancer cell proliferation, chemosensitivity, and multidrug actions: B. Chen et al.; Int. J. High Throughput Screen. 1, 49 (2010), Application, Full Text

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Catalogs
SCREEN-WELL® Compound Libraries
SCREEN-WELL® Compound Libraries
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,